Table 7 Toxicity model report of Geniposide
Classification | Target | Prediction | Probability |
|---|---|---|---|
Organ toxicity | Hepatotoxicity | Inactive | 0.84 |
Toxicity end points | Carcinogenicity | Inactive | 0.85 |
Toxicity end points | Immunotoxicity | Active | 0.52 |
Toxicity end points | Mutagenicity | Inactive | 0.63 |
Toxicity end points | Cytotoxicity | Inactive | 0.66 |
Tox21-Nuclear receptor signaling pathways | Aryl hydrocarbon receptor (AhR) | Inactive | 0.96 |
Tox21-Nuclear receptor signaling pathways | Androgen receptor (AR) | Inactive | 0.94 |
Tox21-Nuclear receptor signaling pathways | Androgen receptor ligand binding domain (AR-LBD) | Inactive | 0.9 |
Tox21-Nuclear receptor signaling pathways | Aromatase | Inactive | 0.9 |
Tox21-Nuclear receptor signaling pathways | Estrogen receptor alpha (ER) | Inactive | 0.68 |
Tox21-Nuclear receptor signaling pathways | Estrogen receptor ligand binding domain (ER-LBD) | Inactive | 0.97 |
Tox21-Nuclear receptor signaling pathways | Peroxisome proliferator activated receptor gamma (PPAR-Gamma) | Inactive | 0.94 |
Tox21-Stress response pathways | Nuclear factor (erythroid-derived 2)-like 2/antioxidant responsive element (nrf2/ARE) | Inactive | 0.96 |
Tox21-Stress response pathways | Heat shock factor response element (HSE) | Inactive | 0.96 |
Tox21-Stress response pathways | Mitochondrial membrane potential (MMP) | Inactive | 0.79 |
Tox21-Stress response pathways | Phosphoprotein (tumor suppressor) p53 | Inactive | 0.9 |
Tox21-Stress response pathways | ATPase family AAA domain-containing protein 5 (ATAD5) | Inactive | 0.96 |